Stay updated on Nivolumab in Pediatric Hypermutant Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page.

Latest updates to the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision label was updated to v3.3.4 and the previous v3.3.3 entry was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedLocations section updated with multiple sites across Massachusetts, Pennsylvania, New South Wales, Queensland, South Australia, British Columbia, and Ontario, and the revision label updated to v3.3.3. The HHS Vulnerability Disclosure link and several regional location entries were removed (Massachusetts, Pennsylvania, New South Wales, Queensland, South Australia, British Columbia, Ontario).SummaryDifference0.8%

- Check60 days agoChange DetectedPublications section now states that publications are automatically filled from PubMed and adds Revision: v3.3.2; the previous PubMed note and Revision: v3.2.0 wording were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check67 days agoChange DetectedDeleted the funding-status notice about potential information delays and the NIH Clinical Center's operating status.SummaryDifference0.4%

- Check81 days agoChange DetectedThe update appears to be cosmetic UI/formatting changes with no modification to core study details such as title, conditions, eligibility criteria, interventions, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check110 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If there are no other changes, this is the main shift.SummaryDifference2%

Stay in the know with updates to Nivolumab in Pediatric Hypermutant Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page.